Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy
Indaptus Therapeutics (Nasdaq: INDP) announced that its Founder and Chief Scientific Officer, Dr. Michael Newman, will participate in a Lumanity webinar on October 23, 2024. The webinar, titled 'Adapting to Immuno-Oncology's R&D Challenges: Refocusing on Innate Immunity as a 'Next Big Thing' in Cancer Immunotherapy,' will explore strategies for modulating innate immune pathways in cancer treatment.
Dr. Newman will share insights from Indaptus' Decoy20 platform, which uses killed, non-pathogenic Gram-negative bacteria to stimulate both innate and adaptive immune responses. The company's unique 'pulse-prime' approach aims to target hard-to-treat cancers that haven't responded to other therapies.
The webinar will feature a panel of biotech leaders discussing the potential of harnessing innate immunity in combination with checkpoint inhibitors to improve cancer control. Dr. Newman emphasized the importance of advancing drugs that modulate innate immune pathways alongside adaptive pathway activation in the evolution of cancer therapy.
Indaptus Therapeutics (Nasdaq: INDP) ha annunciato che il suo Fondatore e Direttore Scientifico, Dr. Michael Newman, parteciperà a un webinar di Lumanity il 23 ottobre 2024. Il webinar, intitolato 'Adattarsi alle Sfide R&S dell'Immuno-Oncologia: Riconsiderare l'Immunità Innata come la 'Prossima Grande Novità' nell'Immunoterapia contro il Cancro,' esplorerà strategie per modulare le vie immunitarie innate nel trattamento del cancro.
Il Dr. Newman condividerà approfondimenti dalla piattaforma Decoy20 di Indaptus, che utilizza batteri Gram-negativi non patogeni e inattivati per stimolare sia le risposte immunitarie innate che quelle adattative. L'unico 'approccio a impulso di priming' dell'azienda mira a colpire tumori difficili da trattare che non hanno risposto ad altre terapie.
Il webinar presenterà un panel di leader nel settore biotech che discuteranno il potenziale di sfruttare l'immunità innata in combinazione con inibitori dei checkpoint per migliorare il controllo del cancro. Il Dr. Newman ha sottolineato l'importanza di sviluppare farmaci che modulano le vie immunitarie innate insieme all'attivazione di vie adattative nell'evoluzione della terapia contro il cancro.
Indaptus Therapeutics (Nasdaq: INDP) anunció que su Fundador y Director Científico, Dr. Michael Newman, participará en un webinar de Lumanity el 23 de octubre de 2024. El webinar, titulado 'Adaptándose a los Desafíos de I+D de la Inmuno-Oncología: Enfocándose en la Inmunidad Innata como la 'Próxima Gran Cosa' en la Inmunoterapia contra el Cáncer,' explorará estrategias para modular las vías inmunitarias innatas en el tratamiento del cáncer.
El Dr. Newman compartirá ideas de la plataforma Decoy20 de Indaptus, que utiliza bacterias Gram-negativas no patógenas y muertas para estimular tanto las respuestas inmunitarias innatas como las adaptativas. El 'enfoque de pulso de priming' único de la empresa busca dirigirse a cánceres difíciles de tratar que no han respondido a otras terapias.
El webinar contará con un panel de líderes biotecnológicos que discutirán el potencial de aprovechar la inmunidad innata en combinación con inhibidores de puntos de control para mejorar el control del cáncer. El Dr. Newman enfatizó la importancia de avanzar en los medicamentos que modulan las vías inmunitarias innatas junto con la activación de las vías adaptativas en la evolución de la terapia contra el cáncer.
인답투스 테라퓨틱스 (Nasdaq: INDP)은 그 창립자이자 최고 과학 책임자인 마이클 뉴먼 박사가 2024년 10월 23일 루마니티 웨비나에 참여할 것이라고 발표했습니다. '면역 종양학의 연구 및 개발 과제에 적응하기: 암 면역 요법에서 '차세대 큰 변화'로서 선천 면역에 재초점을 맞추다'라는 제목의 이 웨비나는 암 치료에서 선천 면역 경로를 조절하는 전략에 대해 탐구할 것입니다.
뉴먼 박사는 인답투스의 디코이20 플랫폼에서 얻은 통찰을 공유할 예정이며, 이 플랫폼은 죽은 비병원성 그람 음성 세균을 사용하여 선천적 및 적응형 면역 반응을 모두 자극합니다. 회사의 독특한 '펄스 프라임 접근법'은 다른 치료법에 반응하지 않은 치료하기 어려운 암을 표적으로 삼는 것을 목표로 합니다.
웨비나에서는 체크포인트 억제제와 결합하여 암 통제를 개선하기 위해 선천 면역을 활용할 가능성을 논의하는 생명공학 리더들로 구성된 패널이 진행됩니다. 뉴먼 박사는 암 치료의 발전에 있어 선천 면역 경로를 조절하는 약물을 발전시키는 것의 중요성을 강조했습니다.
Indaptus Therapeutics (Nasdaq: INDP) a annoncé que son Fondateur et Directeur Scientifique, Dr. Michael Newman, participera à un webinaire Lumanity le 23 octobre 2024. Le webinaire, intitulé 'S'adapter aux Défis R&D de l'Immuno-Oncologie : Réorienter l'Immunité Innée comme la 'Prochaine Grande Chose' en Immunothérapie contre le Cancer,' explorera des stratégies pour moduler les voies immunitaires innées dans le traitement du cancer.
Le Dr. Newman partagera des idées provenant de la plateforme Decoy20 d'Indaptus, qui utilise des bactéries Gram-négatives non pathogènes et tuées pour stimuler à la fois les réponses immunitaires innées et adaptatives. L'unique 'approche à impulsion' de l'entreprise vise à cibler des cancers difficiles à traiter qui n'ont pas répondu à d'autres thérapies.
Le webinaire mettra en vedette un panel de dirigeants du secteur biotechnologique discutant du potentiel de l'immunité innée en combinaison avec des inhibiteurs de points de contrôle pour améliorer le contrôle du cancer. Le Dr. Newman a souligné l'importance de faire progresser les médicaments modulant les voies immunitaires innées aux côtés de l'activation des voies adaptatives dans l'évolution de la thérapie contre le cancer.
Indaptus Therapeutics (Nasdaq: INDP) gab bekannt, dass der Gründer und Chief Scientific Officer Dr. Michael Newman am 23. Oktober 2024 an einem Lumanity-Webinar teilnehmen wird. Das Webinar mit dem Titel 'Anpassung an die Forschungs- und Entwicklungsherausforderungen der Immuno-Onkologie: Fokussierung auf die angeborene Immunität als die 'nächste große Sache' in der Krebsimmuntherapie,' wird Strategien zur Modulation der angeborenen Immunwege bei der Krebsbehandlung untersuchen.
Dr. Newman wird Erkenntnisse von der Decoy20-Plattform von Indaptus teilen, die nicht-pathogene, abgetötete gramnegative Bakterien verwendet, um sowohl angeborene als auch adaptive Immunreaktionen zu stimulieren. Der einzigartige 'Pulse-Prime-Ansatz' des Unternehmens zielt darauf ab, schwer behandelbare Krebsarten zu erreichen, die auf andere Therapeutika nicht angesprochen haben.
Das Webinar wird einen Panel aus Führungskräften der Biotechnologiebranche umfassen, die das Potenzial diskutieren, angeborene Immunität in Kombination mit Checkpoint-Inhibitoren zur Verbesserung der Krebsbekämpfung zu nutzen. Dr. Newman betonte die Bedeutung der Weiterentwicklung von Medikamenten, die angeborene Immunwege modulieren, zusammen mit der Aktivierung adaptiver Wege in der Evolution der Krebstherapie.
- None.
- None.
NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that its Founder and Chief Scientific Officer, Dr. Michael Newman, will participate as a panelist in an upcoming webinar hosted by Lumanity. The webinar, titled "Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as a 'Next Big Thing' in Cancer Immunotherapy," will be held on October 23, 2024.
The webinar will explore the next frontier in cancer immunotherapy: harnessing the power of innate immunity. A distinguished panel of biotech leaders will explore strategies for modulating innate immune pathways, either independently or in combination with checkpoint inhibitors, to help patients' immune systems better control cancer. Dr. Newman will share insights from Indaptus’ pioneering work with its Decoy20 platform, which leverages killed, non-pathogenic Gram-negative bacteria to stimulate both innate and adaptive immune responses. Indaptus’ unique "pulse-prime" approach could offer a new path forward in immunotherapy, targeting hard-to-treat cancers that have not responded to other therapies.
"Immuno-oncology has made significant strides, but we believe that advancing drugs that modulate innate immune pathways in conjunction with adaptive pathway activation will be a critical next step in the evolution of cancer therapy," said Dr. Newman. "This webinar provides an excellent opportunity to discuss the challenges and opportunities in innate immunity."
For more information and to register for the webinar, please visit: https://lumanity.com/events/adapting-to-immuno-oncologys-rd-challenges-refocusing-on-innate-immunity-as-a-next-big-thing-in-cancer-immunotherapy/
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product candidate, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product candidate. Indaptus’ Decoy product candidates have also produced meaningful single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things: our expectations and plans regarding our Phase 1 clinical trial of Decoy20, including the timing and design thereof and expected immune responses as we dose more patients in the multi-dosing part of the trial; the anticipated effects of our product candidates, including Decoy20; the plans and objectives of management for future operations; our research and development activities and costs; the sufficiency of our cash and cash equivalents to fund our ongoing activities and our cash management strategy; and our assessment of financing options to support our corporate strategy. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; conditions and events that raise substantial doubt regarding our ability to continue as going concern; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption “Risk Factors” included in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 12, 2024, our most recent Annual Report on Form 10-K filed with the SEC on March 13, 2024, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com
Media Contact:
Cuttlefish Communications
Shira Derasmo
shira@cuttlefishpr.com
917-280-2497
FAQ
When is Indaptus Therapeutics (INDP) participating in the Lumanity webinar on innate immunity in cancer immunotherapy?
What is the title of the Lumanity webinar featuring Indaptus Therapeutics (INDP)?
Who will represent Indaptus Therapeutics (INDP) at the Lumanity webinar on October 23, 2024?
What technology will Indaptus Therapeutics (INDP) discuss at the Lumanity webinar?
What is the 'pulse-prime' approach mentioned in relation to Indaptus Therapeutics (INDP)?
